AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
Memphasys (MEM) confirms RoXsta device’s capability for high-throughput antioxidant testing.
RoXsta processes multiple samples efficiently in laboratory settings.
Pilot results expand opportunities in precision healthcare diagnostics.
Memphasys Ltd (ASX:MEM), an ASX 200-listed healthcare company, is focused on developing technologies for advanced medical diagnostics. Operating within the biotechnology and diagnostic devices sector, Memphasys engages in the creation of tools that enhance laboratory efficiency and support clinical workflows. The company’s recent development of the RoXsta Mega Cell platform reflects continued innovation within the ASX healthcare space.
RoXsta Platform Demonstrates Laboratory Efficiency
A pilot study involving Memphasys (ASX:MEM) has demonstrated that the RoXsta Mega Cell device is capable of conducting simultaneous antioxidant assays on a high-throughput scale. The laboratory testing confirmed that RoXsta can handle large volumes of samples quickly, supporting clinical environments where rapid testing is essential.
The RoXsta platform operates with integrated automation, enabling high-capacity sample processing. This feature allows diagnostic facilities to improve their operational throughput while maintaining consistent data quality. The ability to manage numerous samples within a short period enhances laboratory responsiveness in healthcare diagnostics.
Accuracy and Scalability of Testing
RoXsta’s testing capabilities were assessed in terms of output precision and scalability. The device delivered consistent antioxidant readings, supporting its use in clinical and research environments. These characteristics are particularly valuable for applications that demand reliability in biochemical measurement.
As oxidative stress monitoring becomes more relevant in medical diagnostics, tools such as RoXsta provide measurable outcomes across diverse patient profiles. The demonstrated accuracy supports further deployment in targeted therapeutic and research fields.
Commercial Applications and Sector Expansion
The RoXsta device aligns with ongoing developments in personalised medicine and clinical laboratory innovation. Its application is positioned across multiple segments requiring oxidative stress evaluation. Memphasys (ASX:MEM) has stated the system is suitable for high-demand environments, contributing to the wider adoption of advanced diagnostic equipment.
With increasing interest in laboratory optimisation, the device’s modular and scalable design adds value in both institutional and private healthcare settings. The findings from this pilot study support expansion into broader diagnostic services across the medical technology sector.
Position of Memphasys in ASX Healthcare Innovations
Memphasys (ASX:MEM) continues to work within the growing ASX healthcare and biotechnology sector by delivering diagnostic solutions for clinical precision. RoXsta joins a portfolio of tools engineered to improve accuracy, throughput, and diagnostic efficiency. These developments reflect the current trajectory of the ASX healthcare segment as it integrates technology-driven solutions into standard medical practice.
